Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results

Brachytherapy

Volumn 13, Issue 5, 2014, Pages 442-449

  Mahal, Brandon A ^a   Ziehr, David R ^a   Hyatt, Andrew S ^a   Neubauer Sugar, Emily H ^a   O'Farrell, Desmond A ^a   O'Leary, Michael P ^a   Steele, Graeme S ^a   Niedermayr, Thomas R ^a   Beard, Clair J ^a   Martin, Neil E ^a   Orio, Peter F ^a   D'Amico, Anthony V ^a   Devlin, Phillip M ^a   Nguyen, Paul L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Brachytherapy; Hydrogel spacer; Prior pelvic irradiation; Prior pelvic radiation; Prostate cancer; Rectal spacer; Salvage

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COLOSTOMY; EXTERNAL BEAM RADIOTHERAPY; FAILURE FREE SURVIVAL; FIBROSIS; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; HYDROGEL; MALE; PATIENT HISTORY OF RADIOTHERAPY; PERSONAL EXPERIENCE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RADIATION DOSE; RECTUM CANCER; RECTUM FISTULA; RECURRENT DISEASE; SALVAGE THERAPY; TOXICITY; URINARY TRACT DISEASE; UROGENITAL TRACT TOXICITY;

BRACHYTHERAPY; HYDROGEL SPACER; PRIOR PELVIC IRRADIATION; PRIOR PELVIC RADIATION; PROSTATE CANCER; RECTAL SPACER; SALVAGE;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; FEASIBILITY STUDIES; FOLLOW-UP STUDIES; HUMANS; HYDROGEL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANS AT RISK; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY DOSAGE; RECTUM; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84906076506     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2014.05.001     Document Type: Article

References (47)

1. Stephenson A.J., Scardino P.T., Bianco F.J., et al. Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 2004, 172:2239-2243.
2. Garzotto M., Wajsman Z. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: Results at 5-year followup. J Urol 1998, 159:950-954. discussion 954-955.
3. Ward J.F., Sebo T.J., Blute M.L., et al. Salvage surgery for radiorecurrent prostate cancer: Contemporary outcomes. J Urol 2005, 173:1156-1160.
4. Long J.P., Fallick M.L., LaRock D.R., et al. Preliminary outcomes following cryosurgical ablation of the prostate in patients with clinically localized prostate carcinoma. J Urol 1998, 159:477-484.
5. Bales G.T., Williams M.J., Sinner M., et al. Short-term outcomes aftercryosurgical ablation of the prostate in men with recurrent prostate carcinoma following radiation therapy. Urology 1995, 46:676-680.
6. Perrotte P., Litwin M.S., McGuire E.J., et al. Quality of life after salvage cryotherapy: The impact of treatment parameters. J Urol 1999, 162:398-402.
7. Izawa J.I., Madsen L.T., Scott S.M., et al. Salvage cryotherapy for recurrent prostate cancer after radiotherapy: Variables affecting patient outcome. J Clin Oncol 2002, 20:2664-2671.
8. Parekh A., Graham P.L., Nguyen P.L. Cancer control and complications of salvage local therapy after failure of radiotherapy for prostate cancer: A systematic review. Semin Radiat Oncol 2013, 23:222-234.
9. Nguyen P.L., Chen M.H., D'Amico A.V., et al. Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: A prospective phase 2 study. Cancer 2007, 110:1485-1492.
10. Kuban D., Pollack A., Huang E., et al. Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2003, 57:1260-1268.
11. Zelefsky M.J., Fuks Z., Hunt M., et al. High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002, 53:1111-1116.
12. Schneider H., Ludwig M., Weidner W., et al. Experience with different questionnaires in the management of patients with CP/CPPS: GPSS, IPSS and NIH-CPSI. World J Urol 2003, 21:116-118. discussion 115.
13. Prada P.J., Fernandez J., Martinez A.A., et al. Transperineal injection of hyaluronic acid in anterior perirectal fat to decrease rectal toxicity from radiation delivered with intensity modulated brachytherapy or EBRT for prostate cancer patients. Int J Radiat Oncol Biol Phys 2007, 69:95-102.
14. Prada P.J., Gonzalez H., Menendez C., et al. Transperineal injection of hyaluronic acid in the anterior perirectal fat to decrease rectal toxicity from radiation delivered with low-dose-rate brachytherapy for prostate cancer patients. Brachytherapy 2009, 8:210-217.
15. Susil R.C., McNutt T.R., DeWeese T.L., et al. Effects of prostate-rectum separation on rectal dose from external beam radiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:1251-1258.
16. Pinkawa M., Klotz J., Djukic V., et al. Learning curve in the application of a hydrogel spacer to protect the rectal wall during radiotherapy of localized prostate cancer. Urology 2013, 82:963-968.
17. Daar E., King L., Nisbet A., et al. Viscosity changes in hyaluronic acid: Irradiation and rheological studies. Appl Radiat Isot 2010, 68:746-750.
18. Wilder R.B., Barme G.A., Gilbert R.F., et al. Cross-linked hyaluronan gel reduces the acute rectal toxicity of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010, 77:824-830.
19. Wilder R.B., Barme G.A., Gilbert R.F., et al. Cross-linked hyaluronan gel improves the quality of life of prostate cancer patients undergoing radiotherapy. Brachytherapy 2011, 10:44-50.
20. Noyes W.R., Hosford C.C., Schultz S.E. Human collagen injections to reduce rectal dose during radiotherapy. Int J Radiat Oncol Biol Phys 2012, 82:1918-1922.
21. Pinkawa M., Piroth M.D., Holy R., et al. Quality of life after intensity-modulated radiotherapy for prostate cancer with a hydrogel spacer. Matched-pair analysis. Strahlenther Onkol 2012, 188:917-925.
22. Pinkawa M., Klotz J., Djukic V., et al. Application of a spacer between prostate and anterior rectal wall to optimize radiotherapy of localized prostate cancer. Strahlenther Onkol 2011, 187:42-43.
23. Uhl M., van Triest B., Eble M.J., et al. Low rectal toxicity after dose escalated IMRT treatment of prostate cancer using an absorbable hydrogel for increasing and maintaining space between the rectum and prostate: Results of a multi-institutional phase II trial. Radiother Oncol 2013, 106:215-219.
24. Song D.Y., Herfarth K.K., Uhl M., et al. A multi-institutional clinical trial of rectal dose reduction via injected polyethylene-glycol hydrogel during intensity modulated radiation therapy for prostate cancer: Analysis of dosimetric outcomes. Int J Radiat Oncol Biol Phys 2013, 87:81-87.
25. Hatiboglu G., Pinkawa M., Vallee J.P., et al. Application technique: Placement of a prostate-rectum spacer in men undergoing prostate radiation therapy. BJU Int 2012, 110:E647-E652.
26. Beydoun N., Bucci J.A., Chin Y.S., et al. First report of transperineal polyethylene glycol hydrogel spacer use to curtail rectal radiation dose after permanent iodine-125 prostate brachytherapy. Brachytherapy 2013, 12:368-374.
27. Lee B., Shinohara K., Weinberg V., et al. Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: The University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2007, 67:1106-1112.
28. Jabbari S., Hsu I.C., Kawakami J., et al. High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience. Brachytherapy 2009, 8:339-344.
29. Niedermayr T.R., Nguyen P.L., Murciano-Goroff Y.R., et al. Placement of empty catheters for an HDR-Emulating LDR prostate (HELP) brachytherapy technique: Comparison to Standard Intraoperative planning. Brachytherapy 2014, [Epub ahead of print].
30. Chang P., Szymanski K.M., Dunn R.L., et al. Expanded prostate cancer index composite for clinical practice: Development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol 2011, 186:865-872.
31. Wei J.T., Dunn R.L., Litwin M.S., et al. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000, 56:899-905.
32. Muanza T.M., Albert P.S., Smith S., et al. Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy. Int J Radiat Oncol Biol Phys 2005, 62:1316-1321.
33. Guedea F., Ferrer M., Pera J., et al. Quality of life two years after radical prostatectomy, prostate brachytherapy or external beam radiotherapy for clinically localised prostate cancer: The Catalan Institute of Oncology/Bellvitge Hospital experience. Clin Transl Oncol 2009, 11:470-478.
34. Kupelian P.A., Reddy C.A., Klein E.A., et al. Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: Preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 2001, 51:988-993.
35. Storey M.R., Pollack A., Zagars G., et al. Complications from radiotherapy dose escalation in prostate cancer: Preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000, 48:635-642.
36. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
37. Cox D. Regression models and life-tables. J R Stat Soc B 1972, 34:187-220.
38. Nguyen P.L., Devlin P.M., Beard C.J., et al. High-dose-rate brachytherapy for prostate cancer in a previously radiated patient with polyethylene glycol hydrogel spacing to reduce rectal dose: Case report and review of the literature. Brachytherapy 2013, 12:77-83.
39. Wong W.W., Buskirk S.J., Schild S.E., et al. Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. J Urol 2006, 176:2020-2024.
40. Grado G.L., Collins J.M., Kriegshauser J.S., et al. Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999, 53:2-10.
41. Beyer D.C. Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology 1999, 54:880-883.
42. Kalakota K., Liauw S.L. Toxicity after external beam radiotherapy for prostate cancer: An analysis of late morbidity in men with diabetes mellitus. Urology 2013, 81:1196-1201.
43. Zelefsky M.J., Cowen D., Fuks Z., et al. Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 1999, 85:2460-2468.
44. Herold D.M., Hanlon A.L., Hanks G.E. Diabetes mellitus: A predictor for late radiation morbidity. Int J Radiat Oncol Biol Phys 1999, 43:475-479.
45. Hunter G.K., Reddy C.A., Klein E.A., et al. Long-term (10-year) gastrointestinal and genitourinary toxicity after treatment with external beam radiotherapy, radical prostatectomy, or brachytherapy for prostate cancer. Prostate Cancer 2012, 2012:853487.
46. Solanki A.A., Liauw S.L. Tobacco use and external beam radiation therapy for prostate cancer: Influence on biochemical control and late toxicity. Cancer 2013, 119:2807-2814.
47. Nguyen P.L., D'Amico A.V., Lee A.K., et al. Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: A systematic review of the literature. Cancer 2007, 110:1417-1428.